• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

监狱环境中的处方阿片类药物滥用:患病率、实践及治疗应对措施的系统评价

Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses.

作者信息

Bi-Mohammed Zanib, Wright Nat M, Hearty Philippa, King Nigel, Gavin Helen

机构信息

University of Leeds, School of Healthcare Baines Wing, LS2 9UT, United Kingdom.

Spectrum Community Health CIC, Hebble Wharf, Wakefield, WF1 5RH, United Kingdom.

出版信息

Drug Alcohol Depend. 2017 Feb 1;171:122-131. doi: 10.1016/j.drugalcdep.2016.11.032. Epub 2016 Dec 14.

DOI:10.1016/j.drugalcdep.2016.11.032
PMID:28086177
Abstract

BACKGROUND

To systematically review the quantitative and qualitative evidence base pertaining to the prevalence, practice of, and treatment response to the diversion of prescribed opiates in the prison setting.

METHODS

Medline, Embase, CINAHL, PsycINFO, Google Scholar, ASSIA and Science Direct databases were searched for papers from 1995 to the present relevant to the abuse of prescribed opiate medication. Identified journals and their reference lists were hand searched for other relevant articles. Of the abstracts identified as relevant, full text papers were retrieved and critiqued against the inclusion criteria for the review.

RESULTS

Three hundred and fifty-five abstracts were identified, leading to 42 full-text articles being retrieved. Of those, 10 papers were included in the review. Significant differences in abuse behaviours between different countries were reported. However, a key theme emerged from the data regarding a culture of nasal administration of prescribed sublingual buprenorphine within some prisons due to both reduced prevalence of injection within prison and reduced supplies of illicit drugs within prison. The buprenorphine/naloxone preparation appears to be less amenable to abuse. The review highlighted a paucity of empirical research pertaining to both prevalence of the phenomenon and treatment responses.

CLINICAL AND RESEARCH IMPLICATIONS

Healthcare providers within prisons need to prescribe opioids in the least abuseable preparation since the risk of abuse is significant, despite widespread processes of supervised dispensing. Prescription medication abuse is not limited to opioids and the predominant drug of abuse in an individual prison can rapidly change according to availability.

摘要

背景

系统评价与监狱环境中处方阿片类药物转移的患病率、行为及治疗反应相关的定量和定性证据。

方法

检索Medline、Embase、CINAHL、PsycINFO、谷歌学术、ASSIA和科学Direct数据库,查找1995年至今与处方阿片类药物滥用相关的论文。对已识别的期刊及其参考文献列表进行手工检索,以查找其他相关文章。从识别出的相关摘要中检索全文论文,并根据综述的纳入标准进行评判。

结果

共识别出355篇摘要,并检索到42篇全文文章。其中,10篇论文被纳入综述。报告了不同国家之间滥用行为的显著差异。然而,数据中出现了一个关键主题,即在一些监狱中,由于监狱内注射率降低和非法药物供应减少,出现了对处方舌下含服丁丙诺啡进行鼻内给药的文化现象。丁丙诺啡/纳洛酮制剂似乎较不易被滥用。该综述强调了关于该现象的患病率和治疗反应的实证研究匮乏。

临床及研究启示

监狱内的医疗服务提供者在开具阿片类药物处方时,应选择最不易被滥用的制剂,因为尽管有广泛的监督配药流程,但滥用风险依然很大。处方药滥用不仅限于阿片类药物,而且单个监狱中主要的滥用药物会根据可得性迅速变化。

相似文献

1
Prescription opioid abuse in prison settings: A systematic review of prevalence, practice and treatment responses.监狱环境中的处方阿片类药物滥用:患病率、实践及治疗应对措施的系统评价
Drug Alcohol Depend. 2017 Feb 1;171:122-131. doi: 10.1016/j.drugalcdep.2016.11.032. Epub 2016 Dec 14.
2
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.在阿片类药物依赖管理中使用长效阿片类药物进行监督给药。
Cochrane Database Syst Rev. 2017 Apr 27;4(4):CD011983. doi: 10.1002/14651858.CD011983.pub2.
3
Buprenorphine for managing opioid withdrawal.丁丙诺啡用于管理阿片类药物戒断。
Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025. doi: 10.1002/14651858.CD002025.pub5.
4
Opioids for cancer pain - an overview of Cochrane reviews.用于癌症疼痛的阿片类药物——Cochrane系统评价综述
Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2.
5
Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.美沙酮和丁丙诺啡用于阿片类药物依赖的管理:系统评价与经济学评估
Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. doi: 10.3310/hta11090.
6
Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.美沙酮与丁丙诺啡治疗阿片类物质使用障碍的有效性:前瞻性队列研究数据的二次分析
BMJ Open. 2025 Jun 17;15(6):e095645. doi: 10.1136/bmjopen-2024-095645.
7
Buprenorphine for the management of opioid withdrawal.丁丙诺啡用于阿片类药物戒断的管理。
Cochrane Database Syst Rev. 2000(3):CD002025. doi: 10.1002/14651858.CD002025.
8
Survivor, family and professional experiences of psychosocial interventions for sexual abuse and violence: a qualitative evidence synthesis.性虐待和暴力的心理社会干预的幸存者、家庭和专业人员的经验:定性证据综合。
Cochrane Database Syst Rev. 2022 Oct 4;10(10):CD013648. doi: 10.1002/14651858.CD013648.pub2.
9
Opioid agonist treatment for people who are dependent on pharmaceutical opioids.阿片类药物成瘾者的阿片类激动剂治疗。
Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD011117. doi: 10.1002/14651858.CD011117.pub3.
10
Improving health in prisons - from evidence to policy to implementation - experiences from the UK.改善监狱健康状况——从证据到政策再到实施——来自英国的经验
Int J Prison Health. 2017 Sep 11;13(3-4):139-167. doi: 10.1108/IJPH-09-2016-0056.

引用本文的文献

1
Patient Satisfaction and Resource Utilization Following Introduction of Long-Acting Injectable Buprenorphine (LAIB) in Scottish Prisons.长效注射用丁丙诺啡(LAIB)引入苏格兰监狱后的患者满意度和资源利用情况
Subst Abuse Rehabil. 2025 Apr 15;16:83-93. doi: 10.2147/SAR.S510467. eCollection 2025.
2
National consensus statement on opioid agonist treatment in custodial settings.关于监禁场所阿片类激动剂治疗的全国共识声明。
Med J Aust. 2025 Mar 17;222(5):262-268. doi: 10.5694/mja2.52603. Epub 2025 Mar 2.
3
Challenges and recommendations for overdose prevention and harm reduction in an era of fentanyl and xylazine: Perspectives of women with opioid use disorder and professionals.
芬太尼和唑吡坦时代下阿片类药物使用障碍女性和专业人士对过量预防和减少伤害的挑战和建议。
Psychol Addict Behav. 2024 Dec;38(8):860-870. doi: 10.1037/adb0001021. Epub 2024 Aug 22.
4
Prescription drugs with potential for misuse in Irish prisons: analysis of national prison prescribing trends, by gender and history of opioid use disorder, 2012 to 2020.爱尔兰监狱中具有潜在滥用风险的处方药物:按性别和阿片类药物使用障碍史分析 2012 年至 2020 年全国监狱配药趋势。
BMC Psychiatry. 2023 Oct 6;23(1):725. doi: 10.1186/s12888-023-05195-9.
5
Detection of methadone and buprenorphine in urine samples from inmates of German prisons.德国监狱囚犯尿液样本中美沙酮和丁丙诺啡的检测。
Front Psychiatry. 2023 Feb 28;14:1139370. doi: 10.3389/fpsyt.2023.1139370. eCollection 2023.
6
Prescription drugs with potential for misuse: protocol for a multi-indicator analysis of supply, detection and the associated health burden in Ireland between 2010 and 2020.潜在滥用风险的处方药物:2010 年至 2020 年期间爱尔兰供应、检测和相关健康负担的多指标分析方案。
BMJ Open. 2023 Mar 2;13(3):e069665. doi: 10.1136/bmjopen-2022-069665.
7
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.新南威尔士州惩教中心的丁丙诺啡储存作为阿片类激动剂治疗:成本模型。
BMC Health Serv Res. 2022 Nov 8;22(1):1326. doi: 10.1186/s12913-022-08687-8.
8
Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail.罕见且可预防:监狱中阿片类药物使用障碍药物转用的认知。
J Subst Abuse Treat. 2022 Jul;138:108746. doi: 10.1016/j.jsat.2022.108746. Epub 2022 Feb 23.
9
Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.加拿大安大略省患有阿片类药物使用障碍(OUD)的联邦监狱服刑人员的阿片类激动剂治疗(OAT)经历与释放计划:一项混合方法研究
BMC Public Health. 2022 Mar 4;22(1):436. doi: 10.1186/s12889-022-12685-0.
10
Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.2014-2020 年加拿大非处方丁丙诺啡-纳洛酮的供应和使用情况。
Int J Drug Policy. 2022 Mar;101:103545. doi: 10.1016/j.drugpo.2021.103545. Epub 2021 Dec 5.